CrossrefInfokarte
Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma
Annals of Hematology · 2025-03 · 104 (3) · 1747-1756
DOI: 10.1007/s00277-025-06271-8 ↗Abstract
Kein Abstract verfügbar.
EUVIMED